



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	251812	LivProtect
ARTG entry for	Medicine Listed	
Sponsor	FIT-BioCeuticals Limited	
Postal Address	Level 4 / 64 Kippax Street, Surry Hills, NSW, 2010 Australia	
ARTG Start Date	29/07/2015	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . LivProtect

Product Type	Single Medicine Product	Effective Date	9/01/2020
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Maintain/support healthy digestion

Aid/assist fat emulsification in the digestive system

Traditionally used in Western herbal medicine to help reduce occurrence of symptoms of indigestion/dyspepsia

Traditionally used in Western herbal medicine to hepatoprotectant/protect the liver.

Traditionally used in Western herbal medicine to liver tonic/Enhance liver health

Traditionally used in Western herbal medicine to promote bile flow from liver/chloretic

Traditionally used in Western herbal medicine to maintain/support healthy liver function

Indication Requirements

Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings



Australian Government
Department of Health
Therapeutic Goods Administration

Not recommended for use by pregnant and lactating women (or words to that effect).

Adults only (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Bupleurum falcatum	20 mg
Equivalent: Bupleurum falcatum	200 mg
Cynara scolymus	80 mg
Equivalent: Cynara scolymus	4 g
Equivalent: Caffeoylquinic acids calculated as cynarin of Cynara scolymus	4 mg
glutathione	20 mg
Silybum marianum	180 mg
Equivalent: Flavanolignans calculated as silybin	144 mg
Equivalent: Silybum marianum	7.2 g

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
Carnauba Wax
colloidal anhydrous silica
croscarmellose sodium
crospovidone
hypromellose
macrogol 400
magnesium stearate
maltodextrin
microcrystalline cellulose
povidone

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary